These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34413148)

  • 21. Definitive radiotherapy for localized follicular lymphoma staged by
    Brady JL; Binkley MS; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Mac Manus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova Y; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Hoppe RT; Mikhaeel NG
    Blood; 2019 Jan; 133(3):237-245. PubMed ID: 30446493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
    Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
    Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individualized positron emission tomography-based isotoxic accelerated radiation therapy is cost-effective compared with conventional radiation therapy: a model-based evaluation.
    Bongers ML; Coupé VM; De Ruysscher D; Oberije C; Lambin P; Uyl-de Groot CA
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):857-65. PubMed ID: 25752401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a Heart Failure Telemonitoring Program Through a Microsimulation Model: Cost-Utility Analysis.
    Boodoo C; Zhang Q; Ross HJ; Alba AC; Laporte A; Seto E
    J Med Internet Res; 2020 Oct; 22(10):e18917. PubMed ID: 33021485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
    Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
    Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
    Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
    Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma.
    Look Hong NJ; Petrella T; Chan K
    J Surg Oncol; 2015 Mar; 111(4):423-30. PubMed ID: 25422047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
    Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
    Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.
    Potnis KC; Di M; Isufi I; Gowda L; Seropian SE; Foss FM; Forman HP; Huntington SF
    Blood Adv; 2023 Mar; 7(5):801-810. PubMed ID: 36342852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness Analysis of PET-CT Surveillance After Treatment of Human Papillomavirus-Positive Oropharyngeal Cancer.
    Lin ME; Castellanos CX; Acevedo JR; Yu JC; Kokot NC
    Otolaryngol Head Neck Surg; 2024 Jan; 170(1):122-131. PubMed ID: 37622527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
    Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK
    Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis.
    Gassert FG; Ziegelmayer S; Luitjens J; Gassert FT; Tollens F; Rink J; Makowski MR; Rübenthaler J; Froelich MF
    Eur Radiol; 2022 Apr; 32(4):2448-2456. PubMed ID: 34837511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
    J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-Effectiveness of CT, CTA, MRI, and Specialized MRI for Evaluation of Patients Presenting to the Emergency Department With Dizziness.
    Tu LH; Melnick E; Venkatesh AK; Sheth KN; Navaratnam D; Yaesoubi R; Forman HP; Mahajan A
    AJR Am J Roentgenol; 2024 Feb; 222(2):e2330060. PubMed ID: 37937837
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.
    Delea TE; Amdahl J; Wang A; Amonkar MM; Thabane M
    Pharmacoeconomics; 2015 Apr; 33(4):367-80. PubMed ID: 25488880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of short-protocol emergency brain MRI after negative non-contrast CT for minor stroke detection.
    Puhr-Westerheide D; Froelich MF; Solyanik O; Gresser E; Reidler P; Fabritius MP; Klein M; Dimitriadis K; Ricke J; Cyran CC; Kunz WG; Kazmierczak PM
    Eur Radiol; 2022 Feb; 32(2):1117-1126. PubMed ID: 34455484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
    Guadagnolo BA; Punglia RS; Kuntz KM; Mauch PM; Ng AK
    J Clin Oncol; 2006 Sep; 24(25):4116-22. PubMed ID: 16943528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.